A Phase I Study of DS-3201B in Subjects With Acute Myelogenous Leukemia (AML) Or Acute Lymphocytic Leukemia (ALL)

Administered By

Awarded By

Contributors

Start/End

  • September 19, 2018 - February 24, 2024